RecruitingNot ApplicableNCT03963622

Careful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19)

Careful Ventilation in Acute Respiratory Distress Syndrome


Sponsor

Unity Health Toronto

Enrollment

740 participants

Start Date

Nov 23, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

This is a multicenter randomized controlled clinical trial with an adaptive design assessing the efficacy of setting the ventilator based on measurements of respiratory mechanics (recruitability and effort) to reduce Day 60 mortality in patients with acute respiratory distress syndrome (ARDS). The CAVIARDS study is also a basket trial; a basket trial design examines a single intervention in multiple disease populations. CAVIARDS consists of an identical 2-arm mechanical ventilation protocol implemented in two different study populations (COVID-19 and non-COVID-19 patients). As per a typical basket trial design, the operational structure of both the COVID-19 substudy (CAVIARDS-19) and non-COVID-19 substudy (CAVIARDS-all) is shared (recruitment, procedures, data collection, analysis, management, etc.).


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Age ≥ 18 y
  • Moderate or severe ARDS (PaO2/FiO2 ≤ 200 mmHg) within 48 h of meeting Berlin ARDS criteria (Patients who were eligible at the time of screening and whose PaO2/FiO2 became > 200 mm Hg under prone positioning when starting the protocol remained eligible)

Exclusion Criteria8

  • Received continuous mechanical ventilation > 7 days
  • Known or clinically suspected elevated intracranial pressure (>18mmHg) necessitating strict control of PaCO2
  • Known pregnancy
  • Broncho-pleural fistula
  • Severe liver disease (Child-Pugh Score ≥ 10)
  • BMI >40kg/m2
  • Anticipating withdrawal of life support and/or shift to palliation as the goal of care
  • Patient is receiving ECMO at time of randomization

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERRespiratory Mechanics

Different maneuvers based on respiratory mechanics will be assessed at the bedside and will be used to individualize ventilator parameters. Recruitability will be assessed with a one breath decremental PEEP maneuver, and search for airway closure with a low-flow pressure volume or pressure-time curve. If the patient has airway closure, the minimal PEEP will be set at the airway opening pressure to avoid closure. If the patient is considered recruitable, the goal is to set PEEP at or above 15cmH20 to maximize alveolar recruitment, until the plateau pressure reaches the safety limit. Volume control ventilation at 6ml·kg-1 will be used. Once spontaneous breathing has started, the occlusion pressure (P0.1) will be maintained within targets.

OTHERStandard Ventilation Strategy

Patients randomized to the control arm will receive standard care. The PEEP is adjusted for oxygenation based on a PEEP-FiO2 table, either the low PEEP-FiO2 or the high PEEP-FiO2 table. Volume targeted ventilation with initial VT 6 mL·kg-1 and Plateau pressure at 30 cmH2O or below, targeting PaO2 60-80 or SpO2 90-95%, adjusted as per the protocol. Pressure-support ventilation is at physician's discretion, but recommended when FiO2 \<60%, and is titrated VT 6-8 mL·kg-1.


Locations(33)

New York University Grossman School of Medicine

New York, New York, United States

Centro de Educación Médica e Investigaciones Clínicas Dr Norberto Quirno (CEMIC)

Buenos Aires, Argentina

Complejo Médico Policía Federal Argentina Churruca Visca

Buenos Aires, Argentina

Hospital Británico de Buenos Aires

Buenos Aires, Argentina

Sanatorio Anchorena Recoleta

Buenos Aires, Argentina

Sanatorio Mater Dei

Buenos Aires, Argentina

Sanatorio Anchorena San Martín

San Martin, Argentina

St. Michael's Hospital

Toronto, Canada

Toronto General Hospital

Toronto, Canada

Toronto Western Hospital

Toronto, Canada

Pontificia Universidad Católica de Chile

Santiago, Chile

CHU Amiens-Picardie

Amiens, France

Centre hospitalier universitaire d'Angers

Angers, France

CH Victor Dupouy

Argenteuil, France

CH de Beauvais

Beauvais, France

CHU Bordeaux - Haut Leveque

Bordeaux, France

Hopital de la Cavale Blanche - CHRU Brest

Brest, France

CH de Cholet

Cholet, France

Hopital Intercommunal de Creteil

Créteil, France

CHU Grenoble-Alpes

Grenoble, France

Hopital Roger Salengro - CHU Lille

Lille, France

Groupe Hospitalier de la Region de Mulhouse et Sud Alsace

Mulhouse, France

Hopital de l'Archet 1 - CHU de Nice

Nice, France

Hopital Europeen Georges-Pompidou

Paris, France

CHU de Poitiers - La Miletrie

Poitiers, France

CH Bretagne Atlantique Vannes-Auray

Vannes, France

HIA Robert Picque

Villenave-d'Ornon, France

Arcispedale Sant'Anna

Ferrara, Italy

University of Foggia

Foggia, Italy

Policlinico Universitario Agostino Gemelli IRCCS

Rome, Italy

OLVG

Amsterdam, North Holland, Netherlands

L'Hospital de la Santa Creu i Sant Pau

Barcelona, Spain

Vall d'Hebron University Hospital

Barcelona, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03963622


Related Trials